| NCT05745727 | A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels | COMPLETED | PHASE1 | 2023-03-23 | 2025-02-06 | 2024-08-26 |
| NCT03180840 | Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks | COMPLETED | PHASE3 | 2017-07-10 | 2020-08-01 | 2020-08-01 |
| NCT02921620 | Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease | WITHDRAWN | PHASE3 | 2017-07 | 2018-07 | 2018-07 |
| NCT03018730 | Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) | COMPLETED | PHASE3 | 2017-05-17 | 2020-01-09 | 2019-12-17 |
| NCT02768974 | Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis | UNKNOWN | PHASE2 | 2016-09 | | 2017-02 |
| NCT02795676 | Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function | COMPLETED | PHASE3 | 2016-06 | 2022-07 | 2021-10 |
| NCT02722122 | Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme® | UNKNOWN | PHASE2 | 2016-05 | | 2017-02 |
| NCT02605590 | Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers | COMPLETED | PHASE1 | 2015-12 | 2016-02 | 2016-02 |
| NCT02107833 | Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers | COMPLETED | PHASE1 | 2014-07 | 2014-12 | 2014-12 |
| NCT02107846 | An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 | COMPLETED | PHASE2 | 2014-04 | 2015-12 | 2015-12 |
| NCT01981720 | Extension Study of PRX-102 for up to 60 Months | COMPLETED | PHASE1, PHASE2 | 2014-01-16 | 2021-11-09 | 2020-08-26 |
| NCT01747980 | Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients | COMPLETED | PHASE1 | 2013-03 | 2014-03 | 2014-01 |
| NCT01678898 | Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients | COMPLETED | PHASE1, PHASE2 | 2012-10 | 2016-03-06 | 2016-03-06 |
| NCT01093859 | An Exploratory Phase 1 Microdose Study of PRX-105 | COMPLETED | EARLY_PHASE1 | 2010-03 | 2010-08 | 2010-05 |
| NCT00258778 | Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD) | COMPLETED | PHASE1 | 2005-11 | 2006-01 | |